CareLit Fachartikel

Atopaxar

Wurster, T.; May, A.-E. · Zeitschrift für Orthopädie und Unfallchirurgie · 2012 · Heft 03 · S. 228 bis 233

Dokument
613579
CareLit-ID
Jahr
2012
Publikation
PDF
nein
Metadaten
DOI
ja
zitierfähig

Bibliografische Angaben

Zeitschrift
Zeitschrift für Orthopädie und Unfallchirurgie
Autor:innen
Wurster, T.; May, A.-E.
Ausgabe
Heft 03 / 2012
Jahrgang 32
Seiten
228 bis 233
Erschienen: 2012-01-01 00:00:00
ISSN
0720-9355;2567-5761
DOI
10.5482/hamo-12-05-0009

Zusammenfassung

SummaryAtopaxar, also known as E 5555 is a novel reversible protease-activated receptor-1 (PAR-1) thrombin receptor antagonist. To date, Atopaxar has been investigated in phase II trials with focus on safety and tolerability in patients with acute coronary syndromes or stable coronary artery disease on top of standard antiplatelet therapy. Atopaxar was generally well tolerated, however a rise in liver enzymes and prolongation of the QTcF interval were observed. The data suggest, that atopaxar administration may promote some minor bleeding complications, but does not seem to significantly increase the risk of maj…

Schlagworte

Atopaxar Phase Safety Patients Coronary Standard Antiplatelet Therapy Suggest Bleeding Efficacy Summaryatopaxar Zeitschrift für Orthopädie und Unfallchirurgie